JP7202362B2 - 組み換えｍｖａ及び抗体の静脈内投与を用いた、がん治療のための併用療法 - Google Patents

組み換えｍｖａ及び抗体の静脈内投与を用いた、がん治療のための併用療法 Download PDF

Info

Publication number
JP7202362B2
JP7202362B2 JP2020511314A JP2020511314A JP7202362B2 JP 7202362 B2 JP7202362 B2 JP 7202362B2 JP 2020511314 A JP2020511314 A JP 2020511314A JP 2020511314 A JP2020511314 A JP 2020511314A JP 7202362 B2 JP7202362 B2 JP 7202362B2
Authority
JP
Japan
Prior art keywords
cancer
mva
her2
cells
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020511314A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020531524A5 (https=
JP2020531524A (ja
Inventor
ホーホライン・フーベルトゥス
ラウターバッハ・ヘニング
メディナ・エチェヴェルツ・ホセ
ハビャン・マティアス
Original Assignee
バヴァリアン・ノルディック・アクティーゼルスカブ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バヴァリアン・ノルディック・アクティーゼルスカブ filed Critical バヴァリアン・ノルディック・アクティーゼルスカブ
Publication of JP2020531524A publication Critical patent/JP2020531524A/ja
Publication of JP2020531524A5 publication Critical patent/JP2020531524A5/ja
Application granted granted Critical
Publication of JP7202362B2 publication Critical patent/JP7202362B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A61K39/285—Vaccinia virus or variola virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2020511314A 2017-08-24 2018-08-23 組み換えｍｖａ及び抗体の静脈内投与を用いた、がん治療のための併用療法 Active JP7202362B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17187824.2 2017-08-24
EP17187824 2017-08-24
PCT/EP2018/072789 WO2019038388A1 (en) 2017-08-24 2018-08-23 POLYTHERAPY FOR THE TREATMENT OF CANCER BY INTRAVENOUS ADMINISTRATION OF RECOMBINANT MVA AND ANTIBODY

Publications (3)

Publication Number Publication Date
JP2020531524A JP2020531524A (ja) 2020-11-05
JP2020531524A5 JP2020531524A5 (https=) 2022-09-07
JP7202362B2 true JP7202362B2 (ja) 2023-01-11

Family

ID=59702586

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020511314A Active JP7202362B2 (ja) 2017-08-24 2018-08-23 組み換えｍｖａ及び抗体の静脈内投与を用いた、がん治療のための併用療法

Country Status (12)

Country Link
US (2) US11273211B2 (https=)
EP (1) EP3691675A1 (https=)
JP (1) JP7202362B2 (https=)
KR (1) KR102754876B1 (https=)
CN (1) CN111050790B (https=)
AU (1) AU2018320417B2 (https=)
BR (1) BR112020003669A2 (https=)
CA (1) CA3073310A1 (https=)
IL (1) IL272546B2 (https=)
MX (1) MX2020001856A (https=)
SG (1) SG11202001115TA (https=)
WO (1) WO2019038388A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
CR20220220A (es) 2019-11-18 2022-09-20 Janssen Biotech Inc Vacunas basadas en calr y jak2 mutantes y sus usos
US20230190922A1 (en) * 2019-11-20 2023-06-22 Bavarian Nordic A/S Recombinant MVA Viruses for Intratumoral and/or Intravenous Administration for Treating Cancer
IL293012A (en) * 2019-11-20 2022-07-01 Bavarian Nordic As Medicinal uses of 4-1bbl modified ankara virus vaccinia ((recombinant mva
US12194157B2 (en) 2020-04-09 2025-01-14 Finncure Oy Carrier for targeted delivery to a host
FI20215508A1 (en) 2020-04-09 2021-10-10 Niemelae Erik Johan Mimetic nanoparticles to prevent the spread of new coronaviruses and reduce the rate of infection
CA3183774A1 (en) * 2020-06-26 2021-12-30 National Breast Cancer Coalition Breast cancer vaccine
EP4175664A2 (en) 2020-07-06 2023-05-10 Janssen Biotech, Inc. Prostate neoantigens and their uses
WO2022192268A1 (en) * 2021-03-10 2022-09-15 University Of Iowa Research Foundation Methods of enhancing antibody therapies

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012524075A (ja) 2009-04-17 2012-10-11 グローブイミューン，インコーポレイテッド 癌に対する併用免疫療法組成物および方法
US20150202272A1 (en) 2012-09-04 2015-07-23 Bavarian Nordic A/S Methods and compositions for enhancing vaccine immune responses
JP2017515837A (ja) 2014-05-13 2017-06-15 バヴァリアン・ノルディック・アクティーゼルスカブ 腫瘍抗原発現組換えポックスウイルス及び免疫チェックポイント分子アンタゴニストまたはアゴニストを用いた癌治療のための併用療法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766598A (en) 1991-03-07 1998-06-16 Virogenetics Corporation Recombinant attenuated ALVAC canarypoxvirus expression vectors containing heterologous DNA segments encoding lentiviral gene products
AU731860B2 (en) 1996-07-25 2001-04-05 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Recombinant pox virus for immunization against tumor-associated antigens
EP1865065A1 (en) * 1998-12-09 2007-12-12 The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services A recombinant vector expressing multiple costimulatory molecules and uses thereof
UA76731C2 (uk) 2000-11-23 2006-09-15 Баваріан Нордік А/С Штам mva-bn модифікованого вірусу коров'ячої віспи ankara, фармацевтична композиція, вакцина, застосування mva-bn для приготування лікарського препарату та для приготування вакцини, спосіб введення гомологічної і/або гетерологічної послідовності нуклеїнової кислоти в клітини-мішені in vitro, спосіб одержання пептиду або білка, спосіб одержання mva-bn, клітина, набір для основної/бустерної імунізації
DE60235041D1 (de) 2001-11-30 2010-02-25 Us Gov Health & Human Serv Und ihre verwendung
EP2345665A3 (en) 2001-12-04 2012-02-15 Bavarian Nordic A/S Flavivirus NS1 subunit vaccine
CN101173282B (zh) * 2003-07-21 2011-04-06 P.安杰莱蒂分子生物学研究所 编码人表皮生长因子2/neu抗原的合成基因及其用途
NZ592082A (en) 2008-11-27 2013-03-28 Bavarian Nordic As Promoters for recombinant viral expression
US8394385B2 (en) 2009-03-13 2013-03-12 Bavarian Nordic A/S Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines
WO2013189611A1 (en) 2012-06-22 2013-12-27 Bavarian Nordic A/S Poxviral vectors for low antibody response after a first priming immunization
WO2014043535A1 (en) 2012-09-14 2014-03-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions for the treatment of cancer
WO2014043518A1 (en) 2012-09-14 2014-03-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Brachyury protein, non-poxvirus non-yeast vectors encoding brachyury protein, and their use
EP2908851A1 (en) 2012-10-19 2015-08-26 Bavarian Nordic Inc. Methods and compositions for the treatment of cancer
EP2912183B1 (en) 2012-10-28 2020-05-06 Bavarian Nordic A/S Pr13.5 promoter for robust t-cell and antibody responses
US9725494B2 (en) * 2013-05-17 2017-08-08 United States Of America, As Represented By The Secretary, Department Of Health And Human Services Soluble CD27 (sCD27) and the use thereof
AU2014347004B2 (en) 2013-11-05 2019-08-08 Bavarian Nordic A/S Combination therapy for treating cancer with a poxvirus expressing a tumor antigen and an antagonist and/or agonist of an immune checkpoint inhibitor
UA127337C2 (uk) * 2013-11-28 2023-07-26 Баваріан Нордік А/С Рекомбінантний поксвірус для індукції посиленої імунної відповіді та його застосування
EP3166646A4 (en) 2014-07-07 2018-03-07 Duke University Vaccines against an oncogenic isoform of her2 (erbb2) and methods of using the same
JP2017530114A (ja) * 2014-09-26 2017-10-12 バヴァリアン・ノルディック・アクティーゼルスカブ フラジェリンをコードする組み換えｍｖａによる鼻腔内免疫のための方法と組成物
ES2901468T3 (es) 2015-07-31 2022-03-22 Bavarian Nordic As Promotores para mejorar la expresión en poxvirus
CA3119503A1 (en) * 2018-11-20 2020-05-28 Bavarian Nordic A/S Therapy for treating cancer with an intratumoral and/or intravenous administration of a recombinant mva encoding 4-1bbl (cd137l) and/or cd40l
IL293012A (en) * 2019-11-20 2022-07-01 Bavarian Nordic As Medicinal uses of 4-1bbl modified ankara virus vaccinia ((recombinant mva
WO2023118508A1 (en) * 2021-12-23 2023-06-29 Bavarian Nordic A/S Recombinant mva viruses for intraperitoneal administration for treating cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012524075A (ja) 2009-04-17 2012-10-11 グローブイミューン，インコーポレイテッド 癌に対する併用免疫療法組成物および方法
US20150202272A1 (en) 2012-09-04 2015-07-23 Bavarian Nordic A/S Methods and compositions for enhancing vaccine immune responses
JP2017515837A (ja) 2014-05-13 2017-06-15 バヴァリアン・ノルディック・アクティーゼルスカブ 腫瘍抗原発現組換えポックスウイルス及び免疫チェックポイント分子アンタゴニストまたはアゴニストを用いた癌治療のための併用療法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
癌と化学療法、2003、Vol. 30, pp.1780-1783

Also Published As

Publication number Publication date
US11273211B2 (en) 2022-03-15
AU2018320417A1 (en) 2020-02-27
WO2019038388A1 (en) 2019-02-28
IL272546A (en) 2020-03-31
KR20200044000A (ko) 2020-04-28
AU2018320417B2 (en) 2024-11-14
IL272546B1 (en) 2023-09-01
JP2020531524A (ja) 2020-11-05
US11723964B2 (en) 2023-08-15
RU2020111588A3 (https=) 2022-03-29
IL272546B2 (en) 2024-01-01
CN111050790A (zh) 2020-04-21
CN111050790B (zh) 2024-07-12
US20220249636A1 (en) 2022-08-11
BR112020003669A2 (pt) 2020-09-01
RU2020111588A (ru) 2021-09-24
MX2020001856A (es) 2020-07-13
CA3073310A1 (en) 2019-02-28
EP3691675A1 (en) 2020-08-12
US20200306352A1 (en) 2020-10-01
KR102754876B1 (ko) 2025-01-13
SG11202001115TA (en) 2020-03-30

Similar Documents

Publication Publication Date Title
JP7202362B2 (ja) 組み換えｍｖａ及び抗体の静脈内投与を用いた、がん治療のための併用療法
AU2019385665B2 (en) Therapy for treating cancer with an intratumoral and/or intravenous administration of a recombinant mva encoding 4-ibbl (cd137l) and/or cd40l
JP2020531524A5 (https=)
JP7555334B2 (ja) 組み換えｍｖａ、及び免疫チェックポイントアンタゴニストまたは免疫チェックポイントアゴニストの静脈内投与によって、がんを治療する併用療法
US20230190922A1 (en) Recombinant MVA Viruses for Intratumoral and/or Intravenous Administration for Treating Cancer
WO2023118508A1 (en) Recombinant mva viruses for intraperitoneal administration for treating cancer
US20250002606A1 (en) Combination Therapy for Treating Cancer with an Antibody and Intravenous Administration of a Recombinant MVA
RU2795103C2 (ru) Комбинированная терапия для лечения рака путем внутривенного введения рекомбинантного mva и антитела
RU2830601C2 (ru) Терапия для лечения рака с помощью внутриопухолевого и/или внутривенного введения рекомбинантного mva, кодирующего 4-1bbl (cd137l) и/или cd40l

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210726

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210726

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220520

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220601

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20220829

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220830

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221214

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221223

R150 Certificate of patent or registration of utility model

Ref document number: 7202362

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250